Specialities

Specialities

Bladder Cancer
Breast Cancer
Colorectal Cancer
COVID-19
Dermatological Cancers
Diagnostics and Screening
Gastrointestinal Cancers
Genitourinary Cancer
Gynaecological Cancers
Haematology
Haematological Malignancies
Head and Neck Cancer
Immunotherapy
Leukaemia
Lymphoma
Multiple Myeloma
Ovarian Cancer
Pancreatic Cancer
Lung Cancer
Prostate Cancer
Renal Cancer
Endocrine Cancers
Paediatric Oncology
Policy
Sarcoma
Supportive Cancer Care
Soft Tissue Tumours
Neuro-oncology
Pathology
Radiology
Radiotherapy
Rare Diseases
Search

Trending Topic

Female doctor hold a virtual of uterus. Woman healthcare, Uterine fibroid, Infertility, Cervical cancer awareness.
13 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Latest in Cervical Cancer Management

Daria Spadaro, Domenica Lorusso

Cervical cancer (CC) is the fourth most common cancer among women worldwide, with an estimated 604,000 new cases and 342,000 CC-related deaths in 2020.1# Approximately 90% of CCs are caused by infection with human papillomavirus (HPV).2 Even though the adoption of both primary (HPV vaccine) and secondary (Pap test and HPV DNA test) preventive measures has […]

touchREVIEWS in Oncology & Haematology. 2025;21(2):1–5:Online ahead of journal publication

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin

CME Accredited Learning

Our accredited content is designed to impact patient health outcomes, by ensuring that it provides you with a learning experience that will positively impact your clinical practice, based on adult learning preferences and intuitive instructional design. All activities are developed in collaboration with leading faculty and education partners.

touchONCOLOGY

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
33 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT FOCUS

HER2 as a targetable biomarker in gastrointestinal oncology

Dr. Yelena Janjigian, Dr Eric Van Cutsem, Prof. Florian Lordick

Three experts discuss HER2 as a targetable biomarker in gastrointestinal oncology

Translations available:
42 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION

Navigating the evolving role of immunotherapy in advanced endometrial carcinoma

Prof. Isabelle Ray-Coquard, Prof. Nicoletta Colombo, Dr Brian Slomovitz

Three experts discuss the evolving role of immunotherapy in treating advanced endometrial cancer

Translations available:
68 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCONGRESS

Navigating the treatment of RRMM with BCMA-directed therapies: Updates from COMy, ASCO and EHA 2025

Prof. Philippe Moreau, Prof. Hermann Einsele, Dr Paola Neri

Three experts discuss latest data from COMy, ASCO and EHA 2025 on BCMA-targeting agents in multiple myeloma.

Translations available:
31 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION

Incorporating ADCs into the treatment of mBC: Practical considerations for the community oncologist

Dr Alison Conlin, Prof. Giuseppe Curigliano

Watch breast cancer oncologists discuss the role of ADCs in the treatment of metastatic breast cancer.

Translations available:
34 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT FOCUS

Multidisciplinary management of TNBC: Integrating immunotherapies for early and metastatic disease

Prof. Sherko Kümmel, Prof. Rebecca Dent, Prof. Peter Schmid

Three experts discuss IO approaches for the treatment of patients with triple-negative breast cancer.

Translations available:
15 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT FOCUS

Applying immunotherapy in clinical practice for patients with early-stage NSCLC

Prof. Jonathan Spicer

Expert insights on the practical application of immunotherapy in early-stage NSCLC

13 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT FOCUS

RET-positive NSCLC: Translating insights into targeted approaches

Dr Christine Bestvina

Watch an expert discuss the key clinical questions surrounding currently approved RET inhibitors in NSCLC.

54 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchSYMPOSIUM

Navigating the clinical impact of TROP2-targeting in NSCLC

Prof. Marina Garassino, Prof. Jaruskha Naidoo, Prof. David Planchard

In this symposium, three lung cancer specialists share their insights on TROP2-targeted ADCs in NSCLC

Translations available:
38 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION

The evolving standard of care for advanced/recurrent endometrial cancer: A practice-focused discussion of immunotherapy

Dr Alexandra Leary, Dr Juan Francisco Grau

Two experts discuss evolving immunotherapy standards of care in advanced/recurrent endometrial cancer.

Translations available:
33 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchMDT

ADCs in metastatic breast cancer: Managing toxicities and optimizing quality of life

Dr Véronique Diéras, Dr Scott Edwards, Dr Kayla Freeman, Mrs Lesley Turner

A multidisciplinary team and a patient advocate discuss antibody–drug conjugate (ADC) related toxicities in metastatic breast cancer.

Translations available:
36 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchMDT

PARP inhibitors for metastatic castration-resistant prostate cancer: Enhancing patient–practitioner conversations

Dr Alicia Morgans, Prof. Albrecht Stenzinger, Dr Grace Cullen, Mr Tony Collier

A multidisciplinary team and a patient advocate discuss use of PARP inhibitors in mCRPC

Translations available:
35 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION

Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals

Dr Marc Steben, Dr Barbara Moscicki

Watch two experts discuss HPV-related disease, vaccination scheduling and strategies to increase uptake.

Translations available:
15 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchFOCUS

Looking to the future in the treatment of steroid-refractory chronic GvHD

Dr Corey Cutler

Expert insights on new and emerging approaches to optimize the management of steroid-refractory cGvHD.

55 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCONGRESS

Updates in BCMA-directed therapies in multiple myeloma from ASH 2024

Prof. Katja Weisel, Dr Nisha Joseph, Prof. Roman Hájek

Three experts discuss data presented at ASH 2024 on BCMA-targeting agents in multiple myeloma.

Translations available:
40 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION

What's new in primary ITP? Key updates from ASH 2024

Dr Hanny Al-Samkari, Dr Drew Provan, Dr Barbara Skopec

Three expert haematologists discuss current and emerging treatments for ITP as well as the disease burden.

Translations available:
29 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT OPINIONS

RAS mutations and personalized cancer care: Targeting the future

Dr David S Hong, Dr Eileen M O’Reilly, Dr Rebecca S Heist

Experts discuss the role of RAS mutations in solid tumours and how they may be targeted to improve outcomes.

Translations available:
20 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchFOCUS

Focused insights: Data implications of ADCs in NSCLC treatment

Prof. Céline Mascaux

Watch a lung cancer expert discuss the latest data for ADCs in NSCLC and their implications for clinical practice.

90 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchSYMPOSIUM

Collaboration in chronic ITP: Improving quality of life and patient outcomes

Prof. Cindy Neunert, Prof. David Kuter, Dr María Eva Mingot Castellano

Leading experts discuss the impact of ITP on patients and review current and emerging treatment strategies.

Load More...

Society & Congress Partners

touchONCOLOGY is proud to partner with leading medical societies and congresses from around the world to bring you news and insight from virtual and live events

View All

All touchIME CME activities are accredited. Learners can claim ACCME, ANCC, ACPE or EBAC credits upon completion of the activities. This content is for healthcare professionals only.

Latest Medical Education - straight to your inbox

Close Popup